Bristol-Myers Squibb Company
BMY
$59.01
-$1.27-2.11%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 7.32% | 5.56% | 2.93% | -0.68% | -2.50% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.32% | 5.56% | 2.93% | -0.68% | -2.50% |
| Cost of Revenue | 13.61% | 10.77% | 9.60% | 10.55% | 7.54% |
| Gross Profit | 5.40% | 4.01% | 1.00% | -3.77% | -5.20% |
| SG&A Expenses | 1.86% | 2.02% | 1.37% | 3.15% | -0.42% |
| Depreciation & Amortization | -1.93% | 3.79% | 0.36% | -3.03% | -5.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.69% | 5.32% | 3.24% | 2.69% | 0.19% |
| Operating Income | 14.16% | 6.60% | 1.63% | -13.39% | -12.37% |
| Income Before Tax | -199.28% | -179.77% | -173.81% | -166.46% | 9.43% |
| Income Tax Expenses | 38.50% | 13.98% | -84.86% | -80.30% | -70.76% |
| Earnings from Continuing Operations | -211.11% | -187.28% | -181.84% | -183.71% | 26.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00% | 38.89% | 7.14% | 27.78% | 16.67% |
| Net Income | -211.50% | -187.60% | -182.14% | -184.09% | 26.84% |
| EBIT | 14.16% | 6.60% | 1.63% | -13.39% | -12.37% |
| EBITDA | 5.60% | 5.30% | 1.14% | -7.57% | -8.60% |
| EPS Basic | -214.24% | -190.62% | -186.04% | -189.43% | 30.29% |
| Normalized Basic EPS | -0.55% | 3.17% | 3.48% | -6.00% | -1.63% |
| EPS Diluted | -214.81% | -191.24% | -186.76% | -190.40% | 30.65% |
| Normalized Diluted EPS | -0.27% | 3.59% | 3.96% | -5.57% | -1.31% |
| Average Basic Shares Outstanding | -2.04% | -3.02% | -3.55% | -3.22% | -2.86% |
| Average Diluted Shares Outstanding | -2.31% | -3.42% | -3.98% | -3.66% | -3.18% |
| Dividend Per Share | 4.76% | 5.26% | 5.33% | 5.41% | 5.48% |
| Payout Ratio | -1.92% | -2.16% | -2.24% | -2.22% | -0.19% |
